FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcu…

FDA approves at-home subcutaneous self-injection initiation for lecanemab (Alzheimer's monoclonal antibody), replacing intravenous infusion clinic visits with 500 mg weekly doses via two 250 mg injections for early disease. This is the first subcutaneous starting option for anti-amyloid AD treatment, removing a major treatment access barrier. If you build home infusion logistics, patient monitoring software, or nurse-dispatch platforms, you just lost your chief AD revenue driver to self-injection. Pivot to chronic management and dosing adherence, or find a new disease.